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Darbepoetin alfa: A new therapeutic agent for renal anemia. rHuEPO three times a week. The use of the subcutane-
Darbepoetin alfa is a super-sialylated analog of human erythro- ous route for rHuEPO administration was first reported
poietin that has a longer circulating half-life in vivo compared in 1988 [5], and most of the evidence suggests that 20 toto both native and recombinant hormone. It has the same
30% lower weekly dosages might be required comparedmechanism of action as erythropoietin, stimulating the same
with intravenous administration [6]. The subcutaneoussurface membrane receptor and triggering the same intracellu-
lar chain of events. An extra two N-linked carbohydrate chains, route is also the only practical one for administering
however, gives darbepoetin alfa greater metabolic stability in rHuEPO to peritoneal dialysis and pre-dialysis patients.
vivo, and its terminal half-life after intravenous administration Although the elimination half-life after subcutaneous ad-is approximately three times longer than for intravenous eryth-
ministration is longer than with IV dosing due to the con-ropoietin. This in turn allows injections of the drug to be given
tinuing absorption from the site of injection, most unitsless frequently, and studies have shown that once-weekly and
once-every-other-week dosing can maintain the hemoglobin have adopted twice- or thrice-weekly dosing regimens.
concentration in patients with renal anemia. The recommended As with other glycoprotein hormones, it was recog-
starting dose for darbepoetin alfa is 0.45 g/kg once weekly nized that the sialic acid residues on erythropoietin werefor both IV and SC administration, with subsequent titration
critical to its metabolic stability in vivo [7]. Once thebased on the hemoglobin concentration. The adverse event
hormone is desialylated, erythropoietin is cleared veryprofile is very similar to that seen with rHuEPO, and no anti-
bodies have been detected in several thousand patients exposed rapidly from the circulation, probably via galactose re-
to the drug, some of whom have been treated for up to five ceptors in the liver [8]. It also was recognized that the
years now. Following a clinical research program that began greater amount of sialic acid residues on the molecule,in November 1996, darbepoetin alfa was finally approved by
the longer the serum half-life, and the greater the degreethe European Commission in June 2001, and by the FDA in
of in vivo biological activity [7]. This led to the hypothesisSeptember 2001.
that increasing the carbohydrate content of naturally
occurring erythropoietin would produce a molecule with
an even longer circulating half-life in vivo, with the po-The advent of recombinant human erythropoietin
tential for enhanced biological activity. This was the ra-(rHuEPO) as a therapeutic agent for the treatment of
tionale for creating a scientific research program thatrenal anemia in the late 1980s transformed the manage-
culminated in the design and large-scale synthesis ofment of this condition, which often previously relied on
novel erythropoiesis-stimulating protein, now called dar-repeated blood transfusions. Treatment with rHuEPO,
bepoetin alfa.which represents supplementation of a hormone-defi-
cient state, has proved highly effective in over a million
patients treated worldwide, and this has been associated
DEVELOPMENT OF DARBEPOETIN ALFAwith significant improvements in general well-being, qual-
Human erythropoietin is a 30,400-dalton glycosylatedity-of-life, exercise tolerance, and cardiac function. Initial
protein containing a 165 amino acid residue backbonestudies conducted in Seattle [1] and London/Oxford [2]
[9]. Attached to this, as a post-translational event, areemployed a thrice-weekly intravenous-dosing regimen
three N-linked and one O-linked carbohydrate chains.that coincided with the visits of the hemodialysis patients
Each of the N-linked chains can contain a maximum ofto the Renal Unit. The relatively short elimination half-
four sialic acid residues, and the O-linked chain canlife after IV administration of around four to eight hours
contain up to two sialic acid residues. The erythropoietinsuggested a rationale for this dosing regimen [3, 4], and
molecule, therefore, may contain anywhere from 4 to 14some units (particularly in the USA) continue to use IV
sialic acid residues [10].
These different isoforms of human erythropoietin may
be separated on a gel using iso-electric focusing, based
on the highly negatively charged sialic acid residues. 2002 by the International Society of Nephrology
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Fig. 1. Hematocrit response following thrice-
weekly intraperitoneal injection of various
isolated recombinant human erythropoietin
(rHuEPO) isoforms in mice. (Data are from
Egrie et al, Glycoconj J 10:263, 1993 [7]; used
with permission.)
Animal experiments in the early 1990s suggested that ular folding and stability. These rHuEPO variants could
then be tested for in vitro and in vivo activity.these different isoforms of erythropoietin had different
biological potency in vivo [7]. Thus, when injected into Before undertaking this endeavor, however, it was
important to determine the appropriate site for the intro-mice intraperitoneally three times a week, isoform 14
showed a much greater hematocrit response than did duction of the extra N-linked chains. In particular, it was
essential that there was no loss of biological activity, andisoform 8 (Fig. 1) [7]. This is despite the fact that isoform
14 has a reduced receptor binding affinity for the erythro- so a series of laborious experiments were conducted to
investigate the effect of changing one amino acid at apoietin receptor compared to the smaller erythropoietin
isoforms. time. A map of the erythropoietin molecule was created,
and a three dimensional model of this suggested thatThe explanation for this effect lies in the metabolic
clearance of the molecule in vivo. Another animal exper- there were two main sites essential for biological activity
of the molecule. These corresponded to the two bindingiment conducted by Egrie et al showed that isoform 14
was cleared very much more slowly from the circulation domains with the erythropoietin receptor [11].
Many new molecules were created, one of them beingwhen injected intravenously into rats, compared to iso-
form 6 (3.8 mL/kg  h compared to 26.8 mL/kg  h; NM279, which contained four N-linked carbohydrate
chains. This showed greater in vivo activity using a mouseFig. 2) [7]. These interesting findings led to the hypothe-
sis that if additional sialic acid residues could be attached ex-hypoxic polycythemic mouse bioassay. Continuing ex-
periments, however, led to the development of NM321to human erythropoietin, then a molecule with an even
longer circulating half-life may be created. (darbepoetin alfa), which contained five N-linked car-
bohydrate chains, the additional two chains attaching atThe strategy for achieving this involved using site-
directed mutagenesis to introduce extra N-linked glycosyl- asparagine residues 30 and 88 (Fig. 3). To achieve this
end, five amino acid substitutions were made to the na-ation consensus sequences into the molecule [11]. These
consensus sequences consisted of three amino acids: (1) tive molecule at the following positions: Ala30Asn,
His32Thr, Pro87Val, Trp88Asn and Pro90Thr [11]. Theasparagine, (2) any amino acid, and (3) a threonine or
serine residue. The plan then was to identify the individ- introduction of the two extra N-linked oligosaccharide
chains increased the potential maximum number of sialicual variants of rHuEPO that had the desired properties,
namely N-linked glycosylation along with similar molec- acid residues from 14 up to 22. The extra carbohydrate
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Fig. 2. Intravenous pharmacokinetics of iso-
lated rHuEPO isoforms in rats. (Data are from
Egrie et al, Glycoconj J 10:263, 1993 [7]; used
with permission.)
(25.0 vs. 7.2 h). The mean clearance of darbepoetin alfa
in dogs was 2.4 mL/kg  h compared to 8.4 mL/kg  h
for rHuEPO (abstract; ibid.).
In another series of experiments, Egrie et al examined
the changes in hematocrit in mice associated with once-
weekly intravenous dosing of darbepoetin alfa (7.5 and
15 g/kg/week) and compared the results with the same
weekly dose of rHuEPO administered thrice weekly (ab-
stract; ibid.). Using a cis-platinum-induced animal model
Fig. 3. Comparison of the structure of darbepoetin alfa and rHuEPO. of anemia in rats, Akahori et al found that weekly IVThe “X”s in darbepoetin alfa represent the five amino acid exchange
administration of darbepoetin alfa (1 g/kg/day) for sixsites that were required to allow the attachment of two extra N-linked
carbohydrate chains. weeks resulted in complete correction of the hematocrit
by the second week of treatment (abstract; Exp Hematol
26:766, 1998). Again, single weekly doses of darbepoetin
alfa were as effective as rHuEPO given three timeson darbepoetin alfa also increased the molecular weight
weekly. The efficacy of darbepoetin alfa in increasing theof the molecule from 30,400 (for native erythropoietin)
hemoglobin concentration also was confirmed in anotherup to 38,000. The carbohydrate content of darbepoetin
anemic rat model induced by immunization with a pepti-alfa is approximately 52%, compared to around 40% for
doglycan-polysaccharide polymer (abstract; Cooke et al,erythropoietin. In vitro, the affinity of darbepoetin alfa
Blood 96:8a, 2000). The dose used in their study wasfor the erythropoietin receptor is less than for the natural
30g/kg every two weeks, and again complete correctionligand, but this is more than compensated for by the
of the anemia was achieved within 28 days of initiatingincreased potency in vivo [11].
treatment.
PRE-CLINICAL STUDIES
PHARMACOKINETIC STUDIES IN HUMANSOne of the earliest experiments compared the pharma-
The first single-dose pharmacokinetic study of darbe-cokinetics of IV darbepoetin alfa with IV rHuEPO in
poetin alfa in humans was initiated in November 1996rats (abstract; Egrie et al, Blood 90:56a, 1997). The mean
[12]. This involved 11 stable continuous ambulatory peri-terminal half-life in vivo was 6.9 hours for darbepoetin
toneal dialysis (CAPD) patients who were given a singlealfa compared with 2.5 hours for rHuEPO, with a cor-
intravenous injection of epoetin alfa (100 U/kg) and therespondingly reduced clearance rate (4.8 vs. 17.7 mL/
equivalent peptide mass of darbepoetin alfa in a double-kg  h). The same experiment was conducted in dogs,
blind randomized manner using a 2 2 crossover design.and again an approximately threefold longer half-life
was obtained for darbepoetin alfa compared to rHuEPO Following a suitable washout period, the absorption of
Macdougal: Darbepoetin alfaS-58
Fig. 4. Pharmacokinetics of darbepoetin alfa
injected intravenously and subcutaneously, com-
pared with rHuEPO injected intravenously at
an equivalent peptide mass in 11 peritoneal
dialysis patients. Data are from [10]; erythro-
poiesis threshold data are based on the range
from the study of Besarab et al [13].
the same dose of darbepoetin alfa injected subcutane- lation of darbepoetin alfa when investigated in over 700
patients with both intravenous and subcutaneous admin-ously was assessed, and compared with the IV pharmaco-
istration for up to one year [14].kinetics of the drug. As with the animal studies, the mean
terminal half-life of IV darbepoetin alfa was threefold
longer than for IV rHuEPO (25.3 vs. 8.5 hours), a differ- CLINICAL STUDIES OF EFFICACY
ence of 16.8 hours (95% confidence interval, 9.4 to 24.2
To date, several clinical trials have reported the effectshours; P 0.0008; Fig. 4). The area under the serum con-
of darbepoetin alfa in treating patients with renal ane-centration-time curve was significantly greater for darbe-
mia, both those on, and those not yet requiring, dialysispoetin alfa (291.0  7.6 vs. 131.9  8.3 ng · h/mL; P 
(abstracts; Macdougall et al, J Am Soc Nephrol 9:258A–0.0005), and clearance was significantly lower (1.6  0.3
259A, 1998; Coyne et al, J Am Soc Nephrol 11:1380,vs. 4.0 0.3 mL/h/kg; P 0.0005). The volume of distri-
2000; Vanrenterghem et al, J Am Soc Nephrol 10:270A,bution was similar for darbepoetin alfa and rHuEPO
1999; Nissenson et al, J Am Soc Nephrol 11:252A, 2000;(52.4  2.0 vs. 48.7  2.1 mL/kg) and is approximately
Graf et al, J Am Soc Nephrol 11:250A, 2000) [15]. Twoequivalent to plasma volume [12].
studies were set up concurrently, with almost identicalIn phase 2 of this study, six patients received 0.5 g/kg
protocols (abstract Macdougall et al, ibid.) [15]. These
of darbepoetin alfa subcutaneously. Serum levels in-
were randomized dose-escalation studies examining the
creased fairly slowly, reaching a peak at around 54 hours efficacy of intravenous darbepoetin alfa in hemodialysis
after injection, and the mean maximum serum concentra- patients and subcutaneous darbepoetin alfa in peritoneal
tion was approximately 10% of that obtained after the dialysis patients. Both protocols involved randomization
same intravenous dose (Fig. 4). The mean half-life of of patients to either once-weekly or thrice-weekly darbe-
darbepoetin alfa after subcutaneous administration was poetin alfa administration, using four sequential dosing
48.8 hours (range 33.5 to 68.0 hours), which was twice regimens (0.075, 0.225, 0.45, and 0.75 g/kg/week). Sev-
as long as that for the intravenous route. At 168 hours enty-eight patients were recruited to the hemodialysis
(7 days) after the SC injection, the mean levels of darbe- study, and 58 patients were recruited to the peritoneal
poetin alfa were still significantly above baseline. The dialysis study. There was a dose-dependent increase in
mean bioavailability of darbepoetin alfa was 36.9%, hemoglobin in both studies with no apparent difference
which was similar to that previously shown for rHuEPO between once and three times weekly dosing with darbe-
[12]. Thus, a single dose of subcutaneous darbepoetin poetin alfa (Figs. 5 and 6). Doses of 0.45 and 0.75 g/
alfa equivalent to 100 U/kg of rHuEPO was able to kg/week provided optimal responses in 60 to 70% of
maintain serum concentrations above 0.1 ng/mL for up patients (defined as a hemoglobin increase of 1 to 3 g/dL
to seven days, a level considered sufficient to stimulate over the first 4 weeks). These results indicated a dose-
erythropoiesis in anemic patients [13]. related erythropoietic response to darbepoetin alfa over
The concern with a longer-acting erythropoietic agent the first four weeks of treatment, and they also suggested
might be that levels of the drug would accumulate with an appropriate starting dose of the drug in the region of
repeated dosing. Evidence from multiple dose pharma- 0.45 to 0.75g/kg/week, administered either intravenously
or subcutaneously (abstract; Macdougall et al, ibid.).cokinetic studies, however, has shown minimal accumu-
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Fig. 5. Dose-response relationship for darbepoetin alfa injected intra-
venously to hemodialysis patients. ROR is the rate of rise of hemoglobin Fig. 7. Comparison of darbepoetin alfa and rHuEPO in maintaining
in g/dL over the first 4 weeks of treatment. hemoglobin levels in a randomized controlled conversion study.
ment was 1.10 g/dL in patients receiving darbepoetin
alfa, and 1.33 g/dL in patients receiving rHuEPO. By 20
weeks, the hemoglobin concentrations in both treatment
groups were within the targeted range of 11 to 13 g/dL
(abstract; Coyne et al, ibid.).
Two studies have examined the effect of switching
patients from rHuEPO to darbepoetin alfa (abstracts;
Vanrenterghem et al and Nissenson et al, ibid.). Thirty-
one centers participated in the European/Australian
study that treated both hemodialysis and peritoneal dial-
ysis patients (abstract; Vanrenterghem et al; ibid.). Pa-
tients on twice- or thrice-weekly rHuEPO were converted
Fig. 6. Dose-response relationship for darbepoetin alfa injected subcu-
to once-weekly darbepoetin alfa, and patients on once-taneously to peritoneal dialysis patients. ROR is the rate of rise of
hemoglobin in g/dL over the first 4 weeks of treatment. weekly rHuEPO were converted to darbepoetin alfa once
every other week. In total, 522 patients were randomized
(347 on darbepoetin alfa and 175 on rHuEPO). The mean
hemoglobin remained stable from baseline to the evalua-Two further studies examining the correction of ane-
tion period for both treatment groups, and there was nomia with darbepoetin alfa were then undertaken (ab-
significant difference between the groups (Fig. 7). At thestract; Coyne et al, ibid.) [15]. The first of these was in
end of the evaluation period, 97% of patients receivingpatients with chronic renal insufficiency not yet requiring
once-weekly darbepoetin alfa and 95% of patients re-dialysis [15], and the second of these was in dialysis
ceiving once-every-other-week darbepoetin alfa werepatients (abstract, Coyne et al, ibid.). The starting dose
successfully treated at the reduced dosing frequenciesof darbepoetin alfa in these two studies was 0.45 g/kg/
(abstract; Vanrenterghem et al; ibid.).week, and the primary end-point was the proportion of
The North American study was conducted in a double-patients achieving a satisfactory hemoglobin response.
blind manner, and a total of 507 hemodialysis patientsOne hundred sixty-six patients were recruited to the
were randomized to receive either IV darbepoetin alfachronic renal insufficiency (CRI) study [15], of whom 129
once weekly plus placebo twice weekly, or to continuereceived darbepoetin alfa (0.45 g/kg once weekly SC),
on intravenous rHuEPO thrice weekly (abstract; Nissen-and the remaining 37 received rHuEPO (50 U/kg twice
son et al, ibid.). The mean hemoglobin remained stableweekly SC). The proportion of patients achieving a satis-
in both treatment groups from baseline to the evaluationfactory hemoglobin response was similar in the two treat-
period, and again there was no statistically significant orment groups (93% darbepoetin alfa, 92% rHuEPO).
clinically relevant difference between the two groups.In the dialysis study, 122 patients were randomized,
The conclusion from both of these studies was thatof whom 91 received darbepoetin alfa (0.45 g/kg once
darbepoetin alfa was as effective as rHuEPO in main-weekly IV or SC) and 31 patients received rHuEPO
taining hemoglobin levels in dialysis patients, but with(50 U/kg three times weekly IV or SC). The mean in-
crease in hemoglobin over the initial four weeks of treat- less frequent dosing. A further open-label study of 703
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Fig. 8. Decline in hemoglobin concentrations
after withholding darbepoetin alfa or rHuEPO
in patients whose hemoglobin was increasing
too excessively.
dialysis patients conducted in Europe and Australia also ANTIBODIES AGAINST DARBEPOETIN ALFA
confirmed the ability of darbepoetin alfa to maintain As stated previously, the amino acid sequence of dar-
hemoglobin levels over a treatment period of one year bepoetin alfa differs from that of native erythropoietin
(abstract; Graf et al, ibid.). at five positions, and it is theoretically possible that these
alterations could make darbepoetin alfa more immuno-
genic. To this end, all patients participating in clinical
ADVERSE EVENT PROFILE trials of darbepoetin alfa had antibodies tested at three
From the clinical trials that have been reported, it monthly intervals. To date, there have been no antibod-
ies detected against darbepoetin alfa in any patient re-has become apparent that darbepoetin alfa possesses an
ceiving treatment for anything up to nearly five years.adverse event profile very similar to that of rHuEPO.
There are also two theoretical reasons why antibodyThe data to support this come from controlled studies
formation might be less of a concern than it might atinvolving 1578 patients receiving darbepoetin alfa and
first seem. First, the tertiary structure of darbepoetin591 patients receiving rHuEPO for up to 24 months
alfa protects the amino acid exchange sites by the carbo-[16]. The overall proportion of patients who discontinued
hydrate side-chains. The latter act as a shield over thetreatment due to adverse events was 2% for darbepoetin
potentially immunogenic amino acid exchange sites.alfa and 4% for rHuEPO. There were no significant
Secondly, the five amino acid substitutions have beendifferences in the incidence of hypertension (23 vs. 26%),
made at a site distinct from the two receptor bindingcerebrovascular disorders (1 vs. 1%), convulsions (1 vs.
sites. This means that any antibodies developing against2%), myocardial infarction (2 vs. 2%), vascular access
darbepoetin alfa would potentially be non-neutralizing,thrombosis (8 vs. 14%), and transient ischemic attack
and thereby have no effect on the biological activity of(1 vs. 1%) for darbepoetin alfa compared with
the molecule. Thus, darbepoetin alfa could still functionrHuEPO. Injection site pain was reported in a number
as an erythropoietic agent.of patients receiving darbepoetin alfa subcutaneously,
but this was generally mild and transient in nature. The
percentage of patients with hemoglobin levels defined CONCLUSIONS
as unstable were similar for darbepoetin alfa (35%) and The development of darbepoetin alfa arose out of
rHuEPO (38%) [16]. In patients whose hemoglobin con- a hypothesis that increasing the sialic acid content of
centration increased to above 14 g/dL, treatment with erythropoietin would generate a molecule that was bio-
darbepoetin alfa or rHuEPO was stopped. The subse- logically more active in vivo. The extra sialylation of the
quent fall in hemoglobin concentration was similar for molecule was achieved by introducing N-linked glycosyl-
32 patients receiving darbepoetin alfa and 15 patients ation consensus sequences using site-directed mutagene-
receiving rHuEPO in the clinical trials where this prob- sis. Darbepoetin alfa is indeed metabolically more stable
in vivo, with a threefold longer half-life than native orlem occurred (Fig. 8) [14].
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tinuous ambulatory peritoneal dialysis patients. Perit Dial Int 9:95–recombinant erythropoietin. The clinical implication of
98, 1989
this is that patients may obtain the same benefits of anemia 5. Bommer J, Barth H-P, Zeier M, et al: Efficacy comparison of
intravenous and subcutaneous recombinant human erythropoietincorrection but with less frequent injections compared with
administration in hemodialysis patients. Contrib Nephrol 88:136–rHuEPO therapy. The studies reported to date have con-
143, 1991
firmed that patients may be maintained on only once- 6. Kaufman JS, Reda DJ, Fye CL, et al: Subcutaneous compared
with intravenous epoetin in patients receiving hemodialysis. N Englweekly or even once-every-other-week dosing, and this
J Med 339:578–583, 1998seems to be true for both IV and SC administration. 7. Egrie JC, Grant JR, Gillies DK, et al: The role of carbohydrate
However, as yet there are no head-to-head studies com- on the biological activity of erythropoietin. Glycoconjugate J 10:
263, 1993paring once-weekly darbepoetin alfa with rHuEPO, and
8. Fukuda MN, Sasaki H, Lopez L, Fukuda M: Survival of recombi-this would be of enormous interest to the nephrological nant erythropoietin in the circulation: The role of carbohydrates.
community. In the meantime, clinical experience with Blood 73:84–89, 1989
9. Davis JM, Arakawa T, Strickland TW, Yphantis DA: Character-darbepoetin alfa in the treatment of renal anemia is
ization of recombinant human erythropoietin produced in Chineseincreasing, as it is in the oncology setting. hamster ovary cells. Biochemistry 26:2633–2638, 1987
10. Sasaki H, Ochi N, Dell A, Fukuda M: Site-specific glycosylation
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